After a long, strange trip, this CEO is close to taking a psilocybin pill to market
Source: Business Insider ·
Compass Pathways is on the cusp of FDA approval for a proprietary version of psilocybin — the active drug in magic mushrooms.
From the source
A lot is riding on the shoulders of Kabir Nath, the CEO of Compass Pathways.Scott Semler for BICompass Pathways wants to use psilocybin to help people with treatment-resistant depression.Its psilocybin pill, COMP360, could finally be coming to market as soon as next year.For its CEO, Kabir Nath, it's been a long, strange trip to get to this point.In 2022, Kabir Nath had a cushy executive job at a pharmaceutical firm that developed anti-psychotic medication.Then he got a call from a scrappy upstart with a patent on a synthetic version of psilocybin — the active ingredient in magic mushrooms. It hoped to use the compound to help those with treatment-resistant depression.They wanted him to join as CEO. Nath, whose father died by suicide, bit on their second pitch."A number of people have said to me in the last couple of years: 'You do realize what a risk that was,'" Nath told Business Insider about eventually jumping ship for what was, and still is, a drug company without FDA approval…